Epic Sciences

11.06.2018 / New York / San Diego Back to News Listings

Blood Test May Identify Cancer Patients Who Respond to PSMA-Targeted Therapies

In a study sponsored by Epic Sciences, San Diego, in partnership with Memorial Sloan Kettering Cancer Center, researchers have demonstrated that a liquid biopsy blood test may be used before treatment is initiated in clinical trials to find patients who are likely to benefit from therapies targeting prostate-specific membrane antigen.1

Developed by Epic Sciences, the blood test looks on the surface of circulating tumor cells (CTCs) for a specific protein, called prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer. In the study, the presence of PSMA-positive CTCs in patients with metastatic prostate cancer was related to the patient’s therapeutic response and clinical outcomes after treatment with an antibody-drug conjugate (ADC) targeting PSMA-positive prostate cancer cells.

Read the full story on CLP Magazine.